
Robin Spiller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/656145/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Functional Bowel Disorders. Gastroenterology, 2006, 130, 1480-1491.	1.3	4,197
2	Bowel Disorders. Gastroenterology, 2016, 150, 1393-1407.e5.	1.3	1,912
3	Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut, 2000, 47, 804-811.	12.1	977
4	Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut, 2013, 62, 159-176.	12.1	776
5	Postinfectious Irritable Bowel Syndrome. Gastroenterology, 2009, 136, 1979-1988.	1.3	690
6	Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut, 2007, 56, 1770-1798.	12.1	677
7	Irritable bowel syndrome. Nature Reviews Disease Primers, 2016, 2, 16014.	30.5	674
8	Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterology and Motility, 2012, 24, 503-512.	3.0	613
9	Eradication of Helicobacter pylori Using Oneâ€week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I Study. Helicobacter, 1996, 1, 138-144.	3.5	562
10	Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology, 2003, 125, 1651-1659.	1.3	521
11	Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ: British Medical Journal, 1997, 314, 779-779.	2.3	503
12	Abnormal Intestinal Permeability in Subgroups of Diarrhea-Predominant Irritable Bowel Syndromes. American Journal of Gastroenterology, 2006, 101, 1288-1294.	0.4	426
13	The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology, 1999, 116, 248-253.	1.3	405
14	The ileal brakeinhibition of jejunal motility after ileal fat perfusion in man Gut, 1984, 25, 365-374.	12.1	396
15	Effect of meal viscosity and nutrients on satiety, intragastric dilution, and emptying assessed by MRI. American Journal of Physiology - Renal Physiology, 2001, 280, G1227-G1233.	3.4	394
16	Postinfectious irritable bowel syndrome1 1Abbreviations used in this paper: EC,_; IBS, irritable bowel syndrome; PI, postinfective Gastroenterology, 2003, 124, 1662-1671.	1.3	393
17	Quantification of Gastrointestinal Liquid Volumes and Distribution Following a 240 mL Dose of Water in the Fasted State. Molecular Pharmaceutics, 2014, 11, 3039-3047.	4.6	360
18	Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterology and Motility, 2007, 19, 62-88.	3.0	310

#	Article	IF	CITATIONS
19	Distinctive Clinical, Psychological, and Histological Features of Postinfective Irritable Bowel Syndrome. American Journal of Gastroenterology, 2003, 98, 1578-1583.	0.4	303
20	Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clinical Gastroenterology and Hepatology, 2005, 3, 349-357.	4.4	299
21	Intestinal Microbiota And Diet in IBS: Causes, Consequences, or Epiphenomena?. American Journal of Gastroenterology, 2015, 110, 278-287.	0.4	283
22	Differential Effects of FODMAPs (Fermentable Oligo-, Di-, Mono-Saccharides and Polyols) on Small and Large Intestinal Contents in Healthy Subjects Shown by MRI. American Journal of Gastroenterology, 2014, 109, 110-119.	0.4	282
23	Faecal microbiota composition and host–microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut, 2014, 63, 1737-1745.	12.1	282
24	Irritable bowel syndrome: a little understood organic bowel disease?. Lancet, The, 2002, 360, 555-564.	13.7	269
25	Antimicrobial Susceptibility Testing of <i>Helicobacter pylori</i> in a Large Multicenter Trial: the MACH 2 Study. Antimicrobial Agents and Chemotherapy, 1999, 43, 2747-2752.	3.2	262
26	In Vivo Imaging of Intragastric Gelation and Its Effect on Satiety in Humans. Journal of Nutrition, 2004, 134, 2293-2300.	2.9	233
27	Further characterisation of the 'ileal brake' reflex in maneffect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY Gut, 1988, 29, 1042-1051.	12.1	232
28	Colon Hypersensitivity to Distension, Rather Than Excessive Gas Production, Produces Carbohydrate-Related Symptoms in Individuals With Irritable Bowel Syndrome. Gastroenterology, 2017, 152, 124-133.e2.	1.3	222
29	Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut, 2002, 51, 410-413.	12.1	219
30	The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. Journal of Antimicrobial Chemotherapy, 1997, 39, 5-12.	3.0	218
31	Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology, 1996, 111, 358-367.	1.3	216
32	Gastric Response to Increased Meal Viscosity Assessed by Echo-Planar Magnetic Resonance Imaging in Humans. Journal of Nutrition, 2000, 130, 122-127.	2.9	216
33	Effects of bowel cleansing on the intestinal microbiota. Gut, 2015, 64, 1562-1568.	12.1	201
34	Serotonin and GI clinical disorders. Neuropharmacology, 2008, 55, 1072-1080.	4.1	196
35	A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut, 2014, 63, 1617-1625.	12.1	187
36	Postprandial Changes in Small Bowel Water Content in Healthy Subjects and Patients With Irritable Bowel Syndrome. Gastroenterology, 2010, 138, 469-477.e1.	1.3	184

#	Article	IF	CITATIONS
37	Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterology and Motility, 2005, 17, 863-870.	3.0	172
38	Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterology and Motility, 2010, 22, 113-133.	3.0	171
39	Role of infection in irritable bowel syndrome. Journal of Gastroenterology, 2007, 42, 41-47.	5.1	164
40	The urea breath test for Helicobacter pylori Gut, 1994, 35, 723-725.	12.1	160
41	Assessment of antral grinding of a model solid meal with echo-planar imaging. American Journal of Physiology - Renal Physiology, 2001, 280, G844-G849.	3.4	160
42	Randomized, doubleâ€blind, placeboâ€controlled trial of prednisolone in postâ€infectious irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2003, 18, 77-84.	3.7	156
43	The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Alimentary Pharmacology and Therapeutics, 2010, 32, 811-820.	3.7	155
44	Review article: probiotics and prebiotics in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2008, 28, 385-396.	3.7	153
45	Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. American Journal of Medicine, 1999, 107, 91-97.	1.5	147
46	Effect of intragastric acid stability of fat emulsions on gastric emptying, plasma lipid profile and postprandial satiety. British Journal of Nutrition, 2009, 101, 919-928.	2.3	144
47	Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFI±. Gut, 2013, 62, 985-994.	12.1	143
48	Ethical Business and Investment: A Model for Business and Society. Journal of Business Ethics, 2000, 27, 149-160.	6.0	135
49	Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5â€HT signalling and metabolism in human disease. Neurogastroenterology and Motility, 2007, 19, 25-31.	3.0	135
50	An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome. Journal of Neurogastroenterology and Motility, 2012, 18, 258-268.	2.4	135
51	Enhancement of intragastric acid stability of a fat emulsion meal delays gastric emptying and increases cholecystokinin release and gallbladder contraction. American Journal of Physiology - Renal Physiology, 2007, 292, G1607-G1613.	3.4	134
52	British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut, 2000, 47, 1ii-19.	12.1	133
53	Relationship of <i>Campylobacter</i> Toxigenicity In Vitro to the Development of Postinfectious Irritable Bowel Syndrome. Journal of Infectious Diseases, 2001, 184, 606-609.	4.0	131
54	Pathogenesis of colonic diverticula. British Journal of Surgery, 2002, 89, 546-554.	0.3	128

#	Article	IF	CITATIONS
55	IBS and IBD — separate entities or on a spectrum?. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 613-621.	17.8	120
56	Fasting and postprandial volumes of the undisturbed colon: normal values and changes in diarrheaâ€predominant irritable bowel syndrome measured using serial <scp>MRI</scp> . Neurogastroenterology and Motility, 2014, 26, 124-130.	3.0	117
57	Post inflammatory damage to the enteric nervous system in diverticular disease and its relationship to symptoms. Neurogastroenterology and Motility, 2009, 21, 847.	3.0	115
58	Concurrent drug use and the risk of perforated colonic diverticular disease: a population-based case-control study. Gut, 2011, 60, 219-224.	12.1	115
59	Gastric emptying of three liquid oral preoperative metabolic preconditioning regimens measured by magnetic resonance imaging in healthy adult volunteers: A randomised double-blind, crossover study. Clinical Nutrition, 2009, 28, 636-641.	5.0	114
60	The DUâ€MACH study: eradication of <i>Helicobacter pylori</i> and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Alimentary Pharmacology and Therapeutics, 1999, 13, 289-295.	3.7	112
61	Impaired Uptake of Serotonin by Platelets From Patients With Irritable Bowel Syndrome Correlates With Duodenal Immune Activation. Gastroenterology, 2011, 140, 1434-1443.e1.	1.3	109
62	Decreased fluid tolerance, accelerated transit, and abnormal motility of the human colon induced by oleic acid. Gastroenterology, 1986, 91, 100-107.	1.3	108
63	The GUâ€MACH study: the effect of 1â€week omeprazole triple therapy on <i>Helicobacter pylori</i> infection in patients with gastric ulcer. Alimentary Pharmacology and Therapeutics, 1999, 13, 703-712.	3.7	108
64	First translational consensus on terminology and definitions of colonic motility in animals and humans studied by manometric and other techniques. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 559-579.	17.8	108
65	Infection, inflammation, and the irritable bowel syndrome. Digestive and Liver Disease, 2009, 41, 844-849.	0.9	105
66	The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls. International Journal of Molecular Sciences, 2019, 20, 433.	4.1	105
67	Visceral hypersensitivity in symptomatic diverticular disease and the role of neuropeptides and low grade inflammation. Neurogastroenterology and Motility, 2012, 24, 318.	3.0	102
68	Inhibitory effect of polyunsaturated fatty acids on the growth of Helicobacter pylori: a possible explanation of the effect of diet on peptic ulceration Gut, 1994, 35, 1557-1561.	12.1	100
69	Patterns of pain in diverticular disease and the influence of acute diverticulitis. European Journal of Gastroenterology and Hepatology, 2003, 15, 1005-1010.	1.6	100
70	Recurrent gastrointestinal bleeding of obscure origin: Report of 17 cases and a guide to logical management. British Journal of Surgery, 2005, 70, 489-493.	0.3	99
71	Antral motility measurements by magnetic resonance imaging. Neurogastroenterology and Motility, 2001, 13, 511-518.	3.0	97
72	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nature Genetics, 2021, 53, 1543-1552.	21.4	96

#	Article	IF	CITATIONS
73	Emptying of the terminal ileum in intact humans. Gastroenterology, 1987, 92, 724-729.	1.3	95
74	Effect of bran, ispaghula, and inert plastic particles on gastric emptying and small bowel transit in humans: the role of physical factors Gut, 1997, 40, 223-227.	12.1	95
75	A Population-Based Study of Perforated Diverticular Disease Incidence and Associated Mortality. Gastroenterology, 2009, 136, 1198-1205.	1.3	95
76	Pharmacology of dietary fibre. , 1994, 62, 407-427.		91
77	Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2000, 14, 155-161.	3.7	87
78	Abnormalities of Serotonin Metabolism and Their Relation to Symptoms in Untreated Celiac Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 874-881.	4.4	86
79	A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut, 2016, 65, 91-99.	12.1	85
80	Non-invasive quantification of small bowel water content by MRI: a validation study. Physics in Medicine and Biology, 2007, 52, 6909-6922.	3.0	82
81	Preventing Gastric Sieving by Blending a Solid/Water Meal Enhances Satiation in Healthy Humans. Journal of Nutrition, 2012, 142, 1253-1258.	2.9	82
82	Moderation of lactulose-induced diarrhea by psyllium: effects on motility and fermentation. American Journal of Clinical Nutrition, 1998, 67, 317-321.	4.7	81
83	Fat delays emptying but increases forward and backward antral flow as assessed by flowâ€sensitive magnetic resonance imaging. Neurogastroenterology and Motility, 1999, 11, 27-36.	3.0	81
84	Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities. International Journal of Pharmaceutics, 2017, 519, 79-97.	5.2	81
85	Healing of duodenal ulcer after eradication of Helicobacter heilmannii. Lancet, The, 1997, 349, 1815-1816.	13.7	80
86	Inflammation as a basis for functional GI disorders. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 641-661.	2.4	79
87	Afferent hypersensitivity in a mouse model of postâ€inflammatory gut dysfunction: role of altered serotonin metabolism. Journal of Physiology, 2008, 586, 4517-4530.	2.9	78
88	Relative importance of abnormalities of CCK and 5â€HT (serotonin) in <i>Giardia</i> â€induced postâ€infectious irritable bowel syndrome and functional dyspepsia. Alimentary Pharmacology and Therapeutics, 2010, 31, 883-891.	3.7	78
89	Post-infectious irritable bowel syndrome. Current Opinion in Gastroenterology, 2006, 22, 13-17.	2.3	77
90	Gastro 2013 APDW/WCOG Shanghai Working Party Report: Chronic diarrhea: Definition, classification, diagnosis. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 6-25.	2.8	77

#	Article	IF	CITATIONS
91	Effect of a novel 5â€HT ₃ receptor agonist MKCâ€733 on upper gastrointestinal motility in humans. Alimentary Pharmacology and Therapeutics, 2003, 18, 1039-1048.	3.7	76
92	Randomized double blind placebo-controlled trial of <i>Saccharomyces cerevisiae</i> CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterology Journal, 2016, 4, 353-362.	3.8	75
93	Delayed gastric emptying and reduced postprandial small bowel water content of equicaloric whole meal bread versus rice meals in healthy subjects: novel MRI insights. European Journal of Clinical Nutrition, 2013, 67, 754-758.	2.9	74
94	A low FODMAP diet is associated with changes in the microbiota and reduction in breath hydrogen but not colonic volume in healthy subjects. PLoS ONE, 2018, 13, e0201410.	2.5	74
95	Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms. American Journal of Gastroenterology, 2002, 97, 2315-2320.	0.4	73
96	Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2003, 18, 569-580.	3.7	73
97	Irritable bowel syndrome, inflammatory bowel disease and the microbiome. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 15-21.	2.3	73
98	Jejunal water and electrolyte absorption from two proprietary enteral feeds in man: importance of sodium content Gut, 1987, 28, 681-687.	12.1	72
99	Use of echo planar imaging to demonstrate the effect of posture on the intragastric distribution and emptying of an oil/water meal. Neurogastroenterology and Motility, 1997, 9, 41-47.	3.0	72
100	The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis. International Journal of Pharmaceutics, 1992, 87, 215-221.	5.2	71
101	Targeting the 5-HT3 receptor in the treatment of irritable bowel syndrome. Current Opinion in Pharmacology, 2011, 11, 68-74.	3.5	71
102	The cortical response to the oral perception of fat emulsions and the effect of taster status. Journal of Neurophysiology, 2011, 105, 2572-2581.	1.8	71
103	Origin of symptoms in diverticular disease. British Journal of Surgery, 2003, 90, 899-908.	0.3	70
104	Magnetic resonance imaging of the behaviour of oil-in-water emulsions in the gastric lumen of man. British Journal of Nutrition, 2006, 95, 331-339.	2.3	70
105	Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit. Gut, 2014, 63, 753-760.	12.1	70
106	Use of ethanol-induced tumor necrosis to palliate dysphagia in patients with esophagogastric cancer. Gastrointestinal Endoscopy, 1990, 36, 43-46.	1.0	66
107	Age-related decline in rectal mucosal lymphocytes and mast cells. European Journal of Gastroenterology and Hepatology, 2004, 16, 1011-1015.	1.6	64
108	Improved methods for fMRI studies of combined taste and aroma stimuli. Journal of Neuroscience Methods, 2006, 158, 186-194.	2.5	64

#	Article	IF	CITATIONS
109	Review article: the pathogenesis and management of acute colonic diverticulitis. Alimentary Pharmacology and Therapeutics, 2014, 39, 359-370.	3.7	62
110	Irritable bowel syndrome. British Medical Bulletin, 2004, 72, 15-29.	6.9	59
111	Enteral Nutrition in Malnourished Patients with Hepatic Cirrhosis and Acute Encephalopathy. Journal of Parenteral and Enteral Nutrition, 1983, 7, 346-350.	2.6	58
112	Influence of protein composition and hydrolysis method on intestinal absorption of protein in man Gut, 1985, 26, 907-913.	12.1	58
113	Role of motility in chronic diarrhoea. Neurogastroenterology and Motility, 2006, 18, 1045-1055.	3.0	58
114	Heterotopic gastric tissue in the duodenum. Digestive Diseases and Sciences, 1982, 27, 880-883.	2.3	56
115	Effect of bran particle size on gastric emptying and small bowel transit in humans: a scintigraphic study Gut, 1995, 37, 216-219.	12.1	56
116	The effect of omeprazole on gastric juice viscosity, pH and bacterial counts. Alimentary Pharmacology and Therapeutics, 1996, 10, 105-109.	3.7	56
117	Role of nerves in enteric infection. Gut, 2002, 51, 759-762.	12.1	56
118	Clinical update: irritable bowel syndrome. Lancet, The, 2007, 369, 1586-1588.	13.7	56
119	Novel <scp>MRI</scp> tests of orocecal transit time and whole gut transit time: studies in normal subjects. Neurogastroenterology and Motility, 2014, 26, 205-214.	3.0	56
120	Measurement of gastric meal and secretion volumes using magnetic resonance imaging. Physics in Medicine and Biology, 2015, 60, 1367-1383.	3.0	55
121	Impact of bitter taste on gastric motility. European Journal of Gastroenterology and Hepatology, 2005, 17, 961-965.	1.6	54
122	Effect of a test meal on the intragastric distribution of urea in the 13C-urea breath test for Helicobacter pylori Gut, 1995, 36, 337-340.	12.1	50
123	Investigation of alginate beads for gastro-intestinal functionality, Part 2: In vivo characterisation. Food Hydrocolloids, 2009, 23, 833-839.	10.7	50
124	Fat Emulsion Intragastric Stability and Droplet Size Modulate Gastrointestinal Responses and Subsequent Food Intake in Young AdultsNitrogen. Journal of Nutrition, 2015, 145, 1170-1177.	2.9	50
125	Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations. International Journal of Pharmaceutics, 1999, 186, 169-175.	5.2	49
126	Genetic variants in <i>CDC42</i> and <i>NXPH1</i> as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. Gut, 2014, 63, 1103-1111.	12.1	49

#	Article	IF	CITATIONS
127	Colonic response to laxative ingestion as assessed by <scp>MRI</scp> differs in constipated irritable bowel syndrome compared to functional constipation. Neurogastroenterology and Motility, 2016, 28, 861-870.	3.0	49
128	Magnetic Resonance Imaging Quantification of Fasted State Colonic Liquid Pockets in Healthy Humans. Molecular Pharmaceutics, 2017, 14, 2629-2638.	4.6	49
129	Scintigraphic demonstration of lactulose-induced accelerated proximal colon transit. Gastroenterology, 1992, 103, 1167-1173.	1.3	48
130	Serotonergic modulating drugs for functional gastrointestinal diseases. British Journal of Clinical Pharmacology, 2002, 54, 11-20.	2.4	48
131	Bowel Disorders. American Journal of Gastroenterology, 2010, 105, 775-785.	0.4	48
132	Is It Diverticular Disease or Is It Irritable Bowel Syndrome?. Digestive Diseases, 2012, 30, 64-69.	1.9	48
133	Changing views on diverticular disease: impact of aging, obesity, diet, and microbiota. Neurogastroenterology and Motility, 2015, 27, 305-312.	3.0	48
134	Demonstration of differences in colonic volumes, transit, chyme consistency, and response to psyllium between healthy and constipated subjects using magnetic resonance imaging. Neurogastroenterology and Motility, 2018, 30, e13400.	3.0	48
135	Effects of serotonin on intestinal secretion and motility. Current Opinion in Gastroenterology, 2001, 17, 99-103.	2.3	48
136	Detection of the intragastric sites at which Helicobacter pylori evades treatment with amoxycillin and cimetidine Gut, 1995, 36, 670-674.	12.1	46
137	Infection, immune function, and functional gut disorders. Clinical Gastroenterology and Hepatology, 2004, 2, 445-455.	4.4	46
138	Stimulation of colonic motility by oral <scp>PEG</scp> electrolyte bowel preparation assessed by <scp>MRI</scp> : comparison of split <i>vs</i> single dose. Neurogastroenterology and Motility, 2014, 26, 1426-1436.	3.0	44
139	Psychological and colonic factors in painful diverticulosis. British Journal of Surgery, 2008, 95, 195-198.	0.3	43
140	The endoscopically abnormal duodenum in patients with dyspepsia: biopsy findings in 60 cases. Histopathology, 1983, 7, 23-34.	2.9	41
141	Regional differences in quinine absorption from the undisturbed human colon assessed using a timed release delivery system. Pharmaceutical Research, 1999, 16, 1087-1092.	3.5	41
142	Serotonin, Inflammation, and IBS: Fitting the Jigsaw Together?. Journal of Pediatric Gastroenterology and Nutrition, 2007, 45, S115-9.	1.8	41
143	Effects of various food ingredients on gall bladder emptying. European Journal of Clinical Nutrition, 2013, 67, 1182-1187.	2.9	41
144	Additive effects of gastric volumes and macronutrient composition on the sensation of postprandial fullness in humans. European Journal of Clinical Nutrition, 2015, 69, 380-384.	2.9	41

#	Article	IF	CITATIONS
145	Delayed mouth-caecum transit of a lactulose labelled liquid test meal in patients with steatorrhoea caused by partially treated coeliac disease Gut, 1987, 28, 1275-1282.	12.1	40
146	Impaired oesophageal transit of capsule versus tablet formulations in the elderly Gut, 1994, 35, 1363-1367.	12.1	40
147	Postâ€infectious IBS: Defining its clinical features and prognosis using an internetâ€based survey. United European Gastroenterology Journal, 2018, 6, 1245-1253.	3.8	40
148	Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Alimentary Pharmacology and Therapeutics, 2017, 46, 282-291.	3.7	39
149	Does cure of Helicobacter pylori infection induce heartburn?. Gastroenterology, 1998, 114, A212.	1.3	38
150	Intestinal absorptive function Gut, 1994, 35, S5-S9.	12.1	37
151	The effects of fasting and refeeding with a â€~metabolic preconditioning' drink on substrate reserves and mononuclear cell mitochondrial function. Clinical Nutrition, 2010, 29, 538-544.	5.0	37
152	Constipation and the Microbiome: Lumen Versus Mucosa!. Gastroenterology, 2016, 150, 300-303.	1.3	37
153	Abnormalities of mucosal serotonin metabolism and 5â€HT ₃ receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron. Alimentary Pharmacology and Therapeutics, 2019, 50, 538-546.	3.7	37
154	The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water. International Journal of Pharmaceutics, 2001, 222, 295-303.	5.2	35
155	A metaâ€∎nalysis of immunogenetic Case–Control Association Studies in irritable bowel syndrome. Neurogastroenterology and Motility, 2015, 27, 717-727.	3.0	35
156	Safety of complementary medicines should be monitored. BMJ: British Medical Journal, 1995, 311, 633-633.	2.3	34
157	Effects of a 5â€HT ₃ antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging. Alimentary Pharmacology and Therapeutics, 2010, 32, 655-663.	3.7	32
158	The shifting interface between IBS and IBD. Current Opinion in Pharmacology, 2011, 11, 586-592.	3.5	32
159	Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment. F1000Research, 2016, 5, 780.	1.6	32
160	Estimating the importance of infection in IBS. American Journal of Gastroenterology, 2003, 98, 238-241.	0.4	31
161	Probiotics: An ideal anti-inflammatory treatment for IBS?. Gastroenterology, 2005, 128, 783-785.	1.3	31
162	Mechanisms underlying effects of kiwifruit on intestinal function shown by MRI in healthy volunteers. Alimentary Pharmacology and Therapeutics, 2019, 49, 759-768.	3.7	31

#	Article	IF	CITATIONS
163	Disruption of colonic barrier function and induction of mediator release by strains of Campylobacter jejuni that invade epithelial cells. World Journal of Gastroenterology, 2008, 14, 7345.	3.3	30
164	Prolonged elevation of galanin and tachykinin expression in mucosal and myenteric enteric nerves in trinitrobenzene sulphonic acid colitis. Neurogastroenterology and Motility, 2008, 20, 392-406.	3.0	29
165	Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging. Journal of Cystic Fibrosis, 2021, 20, 591-597.	0.7	29
166	Impact of Diet on Symptoms of the Irritable Bowel Syndrome. Nutrients, 2021, 13, 575.	4.1	29
167	Scintigraphic Measurements of Canine lleocolonic Transit. Gastroenterology, 1986, 91, 1213-1220.	1.3	28
168	Loxiglumide, a CCK-A Antagonist, in Irritable Bowel Syndrome Annals of the New York Academy of Sciences, 1994, 713, 449-450.	3.8	28
169	Helicobacter pylori eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy. Alimentary Pharmacology and Therapeutics, 1996, 10, 1009-1013.	3.7	28
170	Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects. Alimentary Pharmacology and Therapeutics, 2001, 15, 115-121.	3.7	28
171	Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats. Gut, 2002, 51, 490-495.	12.1	28
172	Serotonergic agents and the irritable bowel syndrome: what goes wrong?. Current Opinion in Pharmacology, 2008, 8, 709-714.	3.5	28
173	Postinfectious Functional Dyspepsia and Postinfectious Irritable Bowel Syndrome: Different Symptoms but Similar Risk Factors. Gastroenterology, 2010, 138, 1660-1663.	1.3	28
174	Distinct Abnormalities of Small Bowel and Regional Colonic Volumes in Subtypes of Irritable Bowel Syndrome Revealed by MRI. American Journal of Gastroenterology, 2017, 112, 346-355.	0.4	28
175	Upper gut dysmotility in slow-transit constipation. European Journal of Gastroenterology and Hepatology, 1999, 11, 693.	1.6	27
176	Echoplanar imaging in GI clinical practice: Assessment of gastric emptying and antral motility in four patients. Journal of Magnetic Resonance Imaging, 2000, 12, 343-346.	3.4	27
177	Fat Emulsification Measured Using NMR Transverse Relaxation. Journal of Magnetic Resonance, 2001, 153, 1-6.	2.1	27
178	Gastric Juice, Gastric Tissue and Blood Antibiotic Concentrations Following Omeprazole, Amoxicillin and Clarithromycin Triple Therapy. Helicobacter, 2003, 8, 294-299.	3.5	27
179	Assessment of motion of colonic contents in the human colon using <scp>MRI</scp> tagging. Neurogastroenterology and Motility, 2017, 29, e13091.	3.0	27
180	Intraluminal Impact of Food: New Insights from MRI. Nutrients, 2019, 11, 1147.	4.1	27

#	Article	IF	CITATIONS
181	SPONTANEOUS RUPTURE OF SPLEEN FOLLOWING STREPTOKINASE THERAPY. Lancet, The, 1989, 334, 1398.	13.7	26
182	Rapid and selective high-performance liquid chromatographic method for the determination of metronidazole and its active metabolite in human plasma, saliva and gastric juice. Biomedical Applications, 1996, 677, 374-379.	1.7	26
183	Inflammatory bowel disease, azathioprine and skin cancer: case report and literature review. European Journal of Gastroenterology and Hepatology, 2001, 13, 193-194.	1.6	26
184	Intragastric Oilâ€inâ€Water Emulsion Fat Fraction Measured Using Inversion Recovery Echoâ€Planar Magnetic Resonance Imaging. Journal of Food Science, 2004, 69, E290.	3.1	26
185	Gut in 2007. Gut, 2007, 56, 1-1.	12.1	26
186	Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: A single-center, single-blind, six-period crossover study in healthy female subjects. Clinical Therapeutics, 2008, 30, 834-844.	2.5	26
187	Spontaneous Dissecting Intramural Haematoma of the Oesophagus: A Rare Cause of Haematemesis and Dysphagia. Endoscopy, 1981, 13, 128-130.	1.8	25
188	Small bowel transit of a bran meal residue in humans: sieving of solids from liquids and response to feeding. Gut, 1998, 42, 685-689.	12.1	25
189	Stool water content and colonic drug absorption: contrasting effects of lactulose and codeine. Pharmaceutical Research, 1999, 16, 1254-1259.	3.5	25
190	Overlap between Irritable Bowel Syndrome and Inflammatory Bowel Disease. Digestive Diseases, 2009, 27, 48-54.	1.9	25
191	NMR relaxometry and rheology of ionic and acid alginate gels. Carbohydrate Polymers, 2010, 82, 663-669.	10.2	25
192	Megaduodenum due to hollow visceral myopathy successfully managed by duodenoplasty and feeding jejunostomy Gut, 1991, 32, 334-337.	12.1	24
193	Proximal colonic response and gastrointestinal transit after high and low fat meals. Digestive Diseases and Sciences, 1993, 38, 1793-1800.	2.3	24
194	ABC of the upper gastrointestinal tract: Anorexia, nausea, vomiting, and pain. BMJ: British Medical Journal, 2001, 323, 1354-1357.	2.3	24
195	Encapsulation of lipid by alginate beads reduces bio-accessibility: An in vivo 13C breath test and MRI study. Food Hydrocolloids, 2011, 25, 1190-1200.	10.7	24
196	Effect of experimental stress on the small bowel and colon in healthy humans. Neurogastroenterology and Motility, 2015, 27, 542-549.	3.0	24
197	How do FODMAPs work?. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 36-39.	2.8	24
198	Impact of polyunsaturated fatty acids on human colonic bacterial metabolism: anin vitroandin vivostudy. British Journal of Nutrition, 1995, 74, 733-741.	2.3	23

#	Article	IF	CITATIONS
199	Night-time quiescence and morning activation in the human colon. European Journal of Gastroenterology and Hepatology, 1999, 11, 1379-1386.	1.6	23
200	Echo-planar magnetic resonance imaging of Gaviscon alginate rafts in-vivo. Journal of Pharmacy and Pharmacology, 2010, 54, 1351-1356.	2.4	23
201	fMRI and MEG analysis of visceral pain in healthy volunteers. Neurogastroenterology and Motility, 2011, 23, 648-e260.	3.0	23
202	The effects of loperamide, or loperamide plus simethicone, on the distribution of gut water as assessed by <scp>MRI</scp> in a mannitol model of secretory diarrhoea. Alimentary Pharmacology and Therapeutics, 2012, 36, 64-73.	3.7	23
203	Aerated drinks increase gastric volume and reduce appetite as assessed by MRI: a randomized, balanced, crossover trial. American Journal of Clinical Nutrition, 2015, 101, 270-278.	4.7	23
204	Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with <i>Clostridium Difficile</i> (RAPID): a randomised placebo controlled trial. Gut, 2019, 68, 1224-1231.	12.1	23
205	Where do all the tablets go in 1986?. Gut, 1986, 27, 879-885.	12.1	22
206	Dissecting intramural haematoma of the oesophagus. QJM - Monthly Journal of the Association of Physicians, 1998, 91, 701-705.	0.5	22
207	Neuropathology of IBS?. Gastroenterology, 2002, 123, 2144-2147.	1.3	22
208	How Inflammation Changes Neuromuscular Function and Its Relevance to Symptoms in Diverticular Disease. Journal of Clinical Gastroenterology, 2006, 40, S117-S120.	2.2	22
209	Irritable bowel syndrome: Bacteria and inflammation—Clinical relevance now. Current Treatment Options in Gastroenterology, 2007, 10, 312-321.	0.8	22
210	Potential Biomarkers. Gastroenterology Clinics of North America, 2011, 40, 121-139.	2.2	22
211	Use of an Immediate Swallow Protocol to Assess Taste and Aroma Integration in fMRI Studies. Chemosensory Perception, 2011, 4, 163-174.	1.2	22
212	Effect of bread gluten content on gastrointestinal function: a crossover MRI study on healthy humans. British Journal of Nutrition, 2016, 115, 55-61.	2.3	22
213	<scp>MRI</scp> assessment of the postprandial gastrointestinal motility and peptide response in healthy humans. Neurogastroenterology and Motility, 2018, 30, e13182.	3.0	22
214	Echo-Planar Imaging Relaxometry to Measure the Viscosity of a Model Meal. Journal of Magnetic Resonance, 1998, 135, 82-86.	2.1	21
215	Monitoring of gallbladder and gastric coordination by EPI. Journal of Magnetic Resonance Imaging, 2005, 21, 82-85.	3.4	21
216	Development and Validation of a Pig Model for Colon-specific Drug Delivery. Journal of Pharmacy and Pharmacology, 2011, 48, 689-693.	2.4	21

#	Article	IF	CITATIONS
217	Magnetic resonance imaging to evaluate gastrointestinal function. Neurogastroenterology and Motility, 2015, 27, 1687-1692.	3.0	21
218	Colon wall motility: comparison of novel quantitative semiâ€automatic measurements using cine <scp>MRI</scp> . Neurogastroenterology and Motility, 2016, 28, 327-335.	3.0	21
219	Glycaemic, gastrointestinal, hormonal and appetitive responses to pearl millet or oats porridge breakfasts: a randomised, crossover trial in healthy humans. British Journal of Nutrition, 2019, 122, 1142-1154.	2.3	21
220	Psyllium reduces inulin-induced colonic gas production in IBS: MRI and <i>in vitro</i> fermentation studies. Gut, 2022, 71, 919-927.	12.1	21
221	Clarification of the link between polyunsaturated fatty acids andHelicobacter pylori-associated duodenal ulcer disease: a dietary intervention study. British Journal of Nutrition, 1997, 78, 515-522.	2.3	20
222	Prior Consumption of a Fat Meal in Healthy Adults Modulates the Brain's Response to Fat. Journal of Nutrition, 2016, 146, 2187-2198.	2.9	20
223	Cholesterol, fibre, and bile acids. Lancet, The, 1996, 347, 415-416.	13.7	19
224	Gallbladder contraction, gastric emptying and antral motility: Single visit assessment of upper GI function in untreated celiac disease using echo-planar MRI. Journal of Magnetic Resonance Imaging, 2005, 22, 634-638.	3.4	19
225	Spatioâ€ŧemporal motility MRI analysis of the stomach and colon. Neurogastroenterology and Motility, 2019, 31, e13557.	3.0	19
226	Glycaemic, gastrointestinal and appetite responses to breakfast porridges from ancient cereal grains: A MRI pilot study in healthy humans. Food Research International, 2019, 118, 49-57.	6.2	19
227	Effect of ileal infusion of glycochenodeoxycholic acid on segmental transit, motility, and flow in the human jejunum and ileum Gut, 1989, 30, 609-617.	12.1	18
228	Diverticular Abscess of the Appendix. Diseases of the Colon and Rectum, 2003, 46, 832-834.	1.3	17
229	Scintigraphic assessment of the intragastric distribution and gastric emptying of an encapsulated drug: the effect of feeding and of a proton pump inhibitor. Alimentary Pharmacology and Therapeutics, 1994, 8, 489-494.	3.7	17
230	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. Neurogastroenterology and Motility, 2021, 33, e14070.	3.0	17
231	Disturbances in large bowel motility. Bailliere's Best Practice and Research in Clinical Gastroenterology, 1999, 13, 397-413.	2.4	16
232	Adult acquired cytomegalovirus infection with gastric and duodenal ulceration Gut, 1988, 29, 1109-1111.	12.1	15
233	Quantitative, noninvasive assessment of antidiarrheal actions of codeine using an experimental model of diarrhea in man. Digestive Diseases and Sciences, 1993, 38, 996-1003.	2.3	15
234	Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia?. European Journal of Gastroenterology and Hepatology, 1999, 11, S29.	1.6	15

#	Article	IF	CITATIONS
235	Identification of Patients with Non-D, Non-C Irritable Bowel Syndrome and Treatment with Renzapride: An Exploratory, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Digestive Diseases and Sciences, 2008, 53, 3191-3200.	2.3	15
236	Delayed postprandial plasma bile acid response in coeliac patients with slow mouth–caecum transit. Clinical Science, 1987, 72, 217-223.	4.3	14
237	Pathological influences on colonic motility: implications for drug delivery. Advanced Drug Delivery Reviews, 1991, 7, 201-218.	13.7	14
238	The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice. British Journal of Clinical Pharmacology, 1997, 44, 245-253.	2.4	14
239	Amoxycillin capsules with omeprazole for the eradication of Helicobacter pylori. Assessment of the importance of antibiotic dose timing in relation to meals. Alimentary Pharmacology and Therapeutics, 1994, 8, 495-498.	3.7	14
240	Modelling sweetness and texture perception in model emulsion systems. European Food Research and Technology, 2008, 227, 537-545.	3.3	14
241	Irritable Bowel Syndrome: Gender, Infection, Lifestyle or What Else?. Digestive Diseases, 2011, 29, 215-221.	1.9	14
242	Editorial: New Thoughts on the Association Between Diverticulosis and Irritable Bowel Syndrome. American Journal of Gastroenterology, 2014, 109, 1906-1908.	0.4	14
243	Do diverticula provide a unique niche for microbiota which can lead to activation of the innate immune system?. Gut, 2017, 66, 1175-1176.	12.1	14
244	Insights Into the Different Effects of Food on Intestinal Secretion Using Magnetic Resonance Imaging. Journal of Parenteral and Enteral Nutrition, 2018, 42, 1342-1348.	2.6	14
245	Gastrointestinal peptides and small-bowel hypomotility are possible causes for fasting and postprandial symptoms in active Crohn's disease. American Journal of Clinical Nutrition, 2020, 111, 131-140.	4.7	14
246	Effect of cholecystectomy on mouth-to-cecum transit of a liquid meal. Digestive Diseases and Sciences, 1988, 33, 19-22.	2.3	13
247	Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection. European Journal of Gastroenterology and Hepatology, 1999, 11, S25.	1.6	13
248	Corticotropin-releasing factor increases ascending colon volume after a fructose test meal in healthy humans: a randomized controlled trial. American Journal of Clinical Nutrition, 2016, 103, 1318-1326.	4.7	13
249	Cine MRI assessment of motility in the unprepared small bowel in the fasting and fed state: Beyond the breathâ€hold. Neurogastroenterology and Motility, 2019, 31, e13466.	3.0	13
250	Processing Apples to Puree or Juice Speeds Gastric Emptying and Reduces Postprandial Intestinal Volumes and Satiety in Healthy Adults. Journal of Nutrition, 2020, 150, 2890-2899.	2.9	13
251	Gastric motility by tagged EPI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 1994, 2, 295-298.	2.0	12
252	Infection as a cause of irritable bowel syndrome. British Journal of Hospital Medicine, 2003, 64, 270-274.	0.2	12

#	Article	IF	CITATIONS
253	Searching for the Answer to Irritable Bowel Syndrome in the Colonic Mucosa: SERTainty and UnSERTainty. Gastroenterology, 2007, 132, 437-441.	1.3	12
254	Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. Trials, 2019, 20, 517.	1.6	12
255	Contrasting effects of viscous and particulate fibers on colonic fermentation in vitro and in vivo, and their impact on intestinal water studied by MRI in a randomized trial. American Journal of Clinical Nutrition, 2020, 112, 595-602.	4.7	12
256	Controversies in Management: Medical treatment works for those with clear diagnosis. BMJ: British Medical Journal, 1994, 309, 1646-1647.	2.3	12
257	Magnetic resonance imaging biomarkers of gastrointestinal motor function and fluid distribution. World Journal of Gastrointestinal Pathophysiology, 2015, 6, 140.	1.0	12
258	Magnetic resonance imaging of the gastrointestinal tract shows reduced small bowel motility and altered chyme in cystic fibrosis compared to controls. Journal of Cystic Fibrosis, 2022, 21, 502-505.	0.7	12
259	Feedforward and Feedback Control Mechanisms in the Gut. Digestive Diseases, 1990, 8, 189-205.	1.9	11
260	Enhanced eradication of Helicobacter pylori by pre- versus post-prandial amoxycillin suspension with omeprazole: implications for antibiotic delivery. Alimentary Pharmacology and Therapeutics, 1996, 10, 631-635.	3.7	11
261	FUNCTIONAL MAGNETIC RESONANCE IMAGING ASSESSMENT OF THE CORTICAL REPRESENTATION OF ORAL VISCOSITY. Journal of Texture Studies, 2007, 38, 725-737.	2.5	11
262	The Effect of Body Position on Flavor Release and Perception: Implications for fMRI Studies. Chemosensory Perception, 2008, 1, 253-257.	1.2	11
263	Do the Symptom-Based, Rome Criteria of Irritable Bowel Syndrome Lead to Better Diagnosis and Treatment Outcomes?. Clinical Gastroenterology and Hepatology, 2010, 8, 125.	4.4	11
264	The Pro Argument. Clinical Gastroenterology and Hepatology, 2010, 8, 125-129.	4.4	11
265	Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial. Trials, 2013, 14, 10.	1.6	11
266	Magnetic resonance spectroscopy measurements of intragastric fat fraction of oil emulsions in humans. European Journal of Lipid Science and Technology, 2015, 117, 31-36.	1.5	11
267	A pilot study of visceral fat and its association with adipokines, stool calprotectin and symptoms in patients with diverticulosis. PLoS ONE, 2019, 14, e0216528.	2.5	11
268	Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine. Journal of Neurogastroenterology and Motility, 2021, 27, 279-291.	2.4	11
269	Echo-planar magnetic resonance imaging to assess water volume in the distal small bowel. Pharmaceutical Research, 1995, 12, 1134-1139.	3.5	10
270	Pharmacotherapy: non-serotonergic mechanisms. Gut, 2002, 51, i87-i90.	12.1	10

#	Article	IF	CITATIONS
271	Magnetic resonance imaging (MRI) insights into how fat emulsion stability alters gastric emptying. Gastroenterology, 2003, 124, A581.	1.3	10
272	OC-119â€Mechanistic randomised control trial of mesalazine in symptomatic diverticular disease: Abstract OC-119 Table 1. Gut, 2012, 61, A51.3-A52.	12.1	10
273	Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. Alimentary Pharmacology and Therapeutics, 1999, 13, 637-642.	3.7	9
274	Is IBS caused by infectious diarrhea?. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 642-643.	1.7	9
275	Anticipation of thermal pain in diverticular disease. Neurogastroenterology and Motility, 2016, 28, 900-913.	3.0	9
276	Inhibiting glucose absorption to treat constipation. The Lancet Gastroenterology and Hepatology, 2018, 3, 588-589.	8.1	9
277	Pain Severity Correlates With Biopsy-Mediated Colonic Afferent Activation But Not Psychological Scores in Patients With IBS-D. Clinical and Translational Gastroenterology, 2021, 12, e00313.	2.5	9
278	In vitro assessment of gastric mucosal transfer of anti-Helicobacter therapeutic agents. Antimicrobial Agents and Chemotherapy, 1997, 41, 1246-1249.	3.2	9
279	Treatment of irritable bowel syndrome. Current Treatment Options in Gastroenterology, 2003, 6, 329-337.	0.8	8
280	Should we treat uncomplicated symptomatic diverticular disease with fibre?. BMJ: British Medical Journal, 2011, 342, d2951-d2951.	2.3	8
281	Diverticular Disease and IBS. Journal of Clinical Gastroenterology, 2016, 50, S29-S32.	2.2	8
282	Feasibility Study of a New Magnetic Resonance Imaging Mini-capsule Device to Measure Whole Gut Transit Time in Paediatric Constipation. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 604-611.	1.8	8
283	Colonic Volume Changes in Paediatric Constipation Compared to Normal Values Measured Using MRI. Diagnostics, 2021, 11, 974.	2.6	8
284	Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants. PLoS ONE, 2020, 15, e0241441.	2.5	8
285	Management of constipation. 2. When fibre fails BMJ: British Medical Journal, 1990, 300, 1064-1063.	2.3	7
286	Mechanisms of postoperative intestinal motor dysfunction. Current Opinion in Gastroenterology, 2003, 19, 103-105.	2.3	7
287	Characterization of the time course of the superior mesenteric, abdominal aorta, internal carotid and vertebral arteries blood flow response to the oral glucose challenge test using magnetic resonance imaging. Physiological Measurement, 2009, 30, 1117-1136.	2.1	7
288	PTH-045â€Effects of an osmotic laxative on the distribution of water between the small and large intestine in humans. Gut, 2010, 59, A141.1-A141.	12.1	7

#	Article	IF	CITATIONS
289	A low calorie morning meal prevents the decline of hepatic glycogen stores: a pilot in vivo ¹³ C magnetic resonance study. Food and Function, 2014, 5, 2237-2242.	4.6	7
290	MR Measures of Small Bowel Wall T2 Are Associated With Increased Permeability. Journal of Magnetic Resonance Imaging, 2021, 53, 1422-1431.	3.4	7
291	Inhibition of Jejunal Water and Electrolyte Absorption by Therapeutic Doses of Clindamycin in Man. Clinical Science, 1984, 67, 117-120.	4.3	6
292	Does Fat Alter the Cortical Response to Flavor?. Chemosensory Perception, 2012, 5, 215-230.	1.2	6
293	Coinfection and Emergence of Rifamycin Resistance during a Recurrent Clostridium difficile Infection. Journal of Clinical Microbiology, 2016, 54, 2689-2694.	3.9	6
294	Simultaneous Measurement of Gastric Emptying of a Soup Test Meal Using MRI and Gamma Scintigraphy. Diagnostics, 2020, 10, 170.	2.6	6
295	Small bowel water content assessed by MRI in health and disease: a collation of single entre studies. Alimentary Pharmacology and Therapeutics, 2022, 55, 327-338.	3.7	6
296	Measurement of GI water content using EPI at 0.5 tesla. Magnetic Resonance Materials in Physics, Biology, and Medicine, 1994, 2, 471-473.	2.0	5
297	Mebeverine decreases mass movements and stool frequency in lactulose-induced diarrhoea. Alimentary Pharmacology and Therapeutics, 1998, 12, 583-588.	3.7	5
298	Nutritional issues in irritable bowel syndrome. Current Opinion in Clinical Nutrition and Metabolic Care, 2001, 4, 537-540.	2.5	5
299	Decreased post-prandial 5-Ht in constipation-predominant irritable bowel syndrome (C-IBS). Gastroenterology, 2003, 124, A137.	1.3	5
300	Potential future therapies for Irritable Bowel Syndrome: Will Disease Modifying Therapy as Opposed to Symptomatic Control Become a Reality?. Gastroenterology Clinics of North America, 2005, 34, 337-354.	2.2	5
301	Esophageal transit of the weekly film-coated risedronate (Actonel®) placebo tablet in subjects with Kyphosis. International Journal of Pharmaceutics, 2006, 311, 20-25.	5.2	5
302	Gut in 2007. Gut, 2007, 56, 1645-1645.	12.1	5
303	Current key developments. Clinical Medicine, 2008, 8, 417-419.	1.9	5
304	Investigation of the behaviour of chitosan microparticles as pH responsive hydrogels in the gastro-intestinal tract using magnetic resonance imaging. Food Hydrocolloids, 2012, 26, 187-196.	10.7	5
305	712 A Multi-Centre, Parallel Group, Randomised Placebo Controlled Trial of Mesalazine for Treatment of Diarrhoea-Predominant Irritable Bowel Syndrome (IBS-D). Gastroenterology, 2014, 146, S-123-S-124.	1.3	5
306	Hidden Dangers of Antibiotic Use: Increased Gut Permeability Mediated by Increased Pancreatic Proteases Reaching the Colon. Cellular and Molecular Gastroenterology and Hepatology, 2018, 6, 347-348.e1.	4.5	5

#	Article	IF	CITATIONS
307	Significance of Postinfectious Irritable Bowel Syndrome?. Gastroenterology, 2019, 156, 14-17.	1.3	5
308	The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome. Journal of Cellular and Molecular Medicine, 2021, 25, 8047-8061.	3.6	5
309	Impact of dietary fiber on absorption from the small intestine. Current Opinion in Gastroenterology, 1999, 15, 100.	2.3	5
310	Application of In Vivo MRI Imaging to Track a Coated Capsule and Its Disintegration in the Gastrointestinal Tract in Human Volunteers. Pharmaceutics, 2022, 14, 270.	4.5	5
311	The effect of protein binding and lipophilicity of penicillins on their in-vitro flux across gastric mucosa. Journal of Antimicrobial Chemotherapy, 1998, 41, 231-236.	3.0	4
312	Magnetic resonance imaging (MRI) assessment of gastric emptying and antral motility in clinical practice: Preliminary results on patients. Gastroenterology, 2000, 118, A392.	1.3	4
313	Peritoneal seeding of pancreatic cancer following transperitoneal biliary procedures. British Journal of Surgery, 2005, 82, 393-393.	0.3	4
314	Preface. Digestive Diseases, 2012, 30, 5-5.	1.9	4
315	Tu1372 Mode of Action of a Macrogol Formulation on Distribution of Intestinal Fluid: A MRI Study. Gastroenterology, 2012, 142, S-814.	1.3	4
316	OC-070â€Dietary Supplementation With Fodmaps Increases Fasting Colonic Volume And Breath Hydrogen In Healthy Volunteers: A Mechanistic Study Using Mri. Gut, 2014, 63, A35.1-A35.	12.1	4
317	Role of microbiota in the pathogenesis of functional disorders of the lower <scp>Gl</scp> tract: Work in progress. Neurogastroenterology and Motility, 2017, 29, 1-5.	3.0	4
318	Increased fasting smallâ€bowel water content in untreated coeliac disease and scleroderma as assessed by magnetic resonance imaging. United European Gastroenterology Journal, 2019, 7, 1353-1360.	3.8	4
319	Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial. Efficacy and Mechanism Evaluation, 2015, 2, 1-62.	0.7	4
320	Effect of omeprazole on the distribution of antibiotics in gastric juice. Gastroenterology, 1995, 108, A102.	1.3	3
321	Postinfective bowel dysfunction. Current Opinion in Gastroenterology, 1997, 13, 85-89.	2.3	3
322	Haute cuisine and the colon. Gut, 2000, 46, 150-151.	12.1	3
323	Bacterial toxins influence long term bowel dysfunction following campylobacter enteritis. Gastroenterology, 2000, 118, A702.	1.3	3
324	MRI assessment of the grinding forces in the antrum. effects of solid food breakdown strength and meal viscosity on gastric emptying and satiety. Gastroenterology, 2000, 118, A142.	1.3	3

#	Article	IF	CITATIONS
325	Relationship between inflammatory response and long term enteroendocrine cell hyperplasia following infection with trichinella spiralis: Effect of corticosteroids. Gastroenterology, 2003, 124, A346.	1.3	3
326	New Insights Into Bloating and Abdominal Distension: Is It All Outlet Obstruction?. American Journal of Gastroenterology, 2010, 105, 888-889.	0.4	3
327	Identifying and testing candidate genes underlying the inflammatory basis of irritable bowel syndrome. Gut, 2011, 60, A164-A164.	12.1	3
328	The MRI colonic function test: Reproducibility of the Macrogol stimulus challenge. Neurogastroenterology and Motility, 2020, 32, e13942.	3.0	3
329	Colonic diverticular disease. Clinical Evidence, 2007, 2007, .	0.2	3
330	Colonic diverticular disease. Clinical Evidence, 2011, 2011, .	0.2	3
331	Noninvasive echo-planar imaging (EPI) monitoring of intragastric viscosity, dilution and emptying of viscous meals in normal subjects. Gastroenterology, 1998, 114, A798.	1.3	2
332	An unusual cystic lesion of liver. Gut, 2006, 55, 742-742.	12.1	2
333	640 The Incidence of and Mortality Associated with Perforated Colonic Diverticular Disease in the UK: A General Population Based Study. Gastroenterology, 2008, 134, A-91-A-92.	1.3	2
334	680 Elevated Chemokine mRNA in Rectal Mucosa Following Gastrointestinal Infection and in Irritable Bowel Syndrome. Gastroenterology, 2009, 136, A-105-A-106.	1.3	2
335	Brain Imaging. , 0, , 319-350.		2
336	Origin of increased fecal serine protease in patients with irritable bowel syndrome and diarrhoea (IBS-D). Gut, 2011, 60, A25-A25.	12.1	2
337	OC-090â€Different effects of FODMAP (fermentable oligo-, di-, and mono-saccharides, and polyols) components on small bowel water content: an MRI study. Gut, 2012, 61, A39.2-A39.	12.1	2
338	Cortical differences in diverticular disease and correlation with symptom reports. Neurogastroenterology and Motility, 2018, 30, e13303.	3.0	2
339	The role of polysaccharides in the gastric processing of foods. Special Publication - Royal Society of Chemistry, 2007, , 342-348.	0.0	2
340	Serotonin type 3 receptor subunit gene polymorphisms associated with psychosomatic symptoms in irritable bowel syndrome: A multicenter retrospective study. World Journal of Gastroenterology, 2022, 28, 2334-2349.	3.3	2
341	Auswirkungen unterschiedlicher Anzuchtbedingungen auf die Populationsstruktur wÄ ¤ rend der Larvalentwicklung vonGilpinia hercyniaeHtg. (Hym., Diprionidae). Journal of Applied Entomology, 1988, 105, 229-248.	1.8	1
342	Small intestinal motility. Current Opinion in Gastroenterology, 1990, 6, 298-304.	2.3	1

#	Article	IF	CITATIONS
343	Small intestine. Current Opinion in Gastroenterology, 1993, 9, 191-194.	2.3	1
344	Effect of ileal nutrients on upper gut function. Commentary. Current Opinion in Gastroenterology, 1995, 11, 97-100.	2.3	1
345	Region selective drug deliver to the colon. Gastroenterology, 1995, 108, A613.	1.3	1
346	Once-a-day treatment of Helicobacter pylori. Gastroenterology, 1998, 114, A134.	1.3	1
347	Increased small bowel but not colonic permeability in post-infectious irritable bowel syndrome. Gastroenterology, 1998, 114, A763.	1.3	1
348	Relation between inflammatory and non-inflammatory pain in diverticular disease. Gastroenterology, 2000, 118, A1197.	1.3	1
349	A change at the tiller. Gut, 2003, 52, 917-917.	12.1	1
350	Increased Expression of Galanin in Mucosal Nerves of Patients with Painful Diverticular Disease. Clinical Science, 2003, 104, 35P-35P.	0.0	1
351	Diarrhea-Predominant Bowel Disorders Following Inflammation and Infection. , 0, , 188-200.		1
352	Information Assimilation and Distribution Challenges and Goals for Real and Virtual Journals. Journal of Clinical Gastroenterology, 2005, 39, 181-188.	2.2	1
353	Recurrent gastrointestinal bleeding of obscure origin. British Journal of Surgery, 2005, 70, 746-746.	0.3	1
354	Copious amounts of ascites. Gut, 2006, 55, 702-702.	12.1	1
355	Chronic diarrhoea. Gut, 2007, 56, 1756-1757.	12.1	1
356	Lymph nodes in gastrointestinal tract. Gut, 2007, 56, 905-905.	12.1	1
357	Preface. Digestive Diseases, 2009, 27, 1-2.	1.9	1
358	Techniques for assessing the functional response to food of the stomach and small and large intestine. , 2009, , 362-386.		1
359	Association of Proinflammatory Genetic Polymorphisms With the Irritable Bowel Syndrome (IBS): Phenotype and Genotype Correlation. Gastroenterology, 2011, 140, S-525.	1.3	1
360	Pain Cortical Processing in Symptomatic Diverticular Disease: A Functional Magnetic Resonance Imaging Study. Gastroenterology, 2011, 140, S-368.	1.3	1

#	Article	IF	CITATIONS
361	PWE-052â€Phenotyping the early morning rush (EMR) in patients with diarrhoea predominant irritable bowel syndrome (IBS-D). Gut, 2012, 61, A318.1-A318.	12.1	1
362	Su2056 Novel MRI Techniques and Parameters for Assessing the Impact of Laxatives on the Human Colon. Gastroenterology, 2014, 146, S-534.	1.3	1
363	PWE-161â€The Macrogol Drink Test To Distinguish Functional Constipation (fc) And Constipation Predominant Irritable Bowel Syndrome (ibs-c): Underlying Mechanisms Demonstrated Using Mri: Abstract PWE-161 Table 1. Gut, 2014, 63, A195.1-A195.	12.1	1
364	OC-114ÂEffect of the low fodmap diet and oligofructose supplement on colonic volume, transit and fermentation: a double-blind randomised controlled trial using magnetic resonance imaging in healthy volunteers. Gut, 2015, 64, A57.1-A57.	12.1	1
365	OC-068â€Measuring the Effect of Ispaghula on Gut Content and Function Using MRI. Gut, 2016, 65, A40.2-A41.	12.1	1
366	OC-088â€Associations Between Microbiota, Colonic Volume and Transit During A Low Fodmap Diet. Gut, 2016, 65, A51.2-A52.	12.1	1
367	67 The Activation of Serosal Nociceptors by Biopsy Supernatants From Patients With Diarrhoea Predominant Irritable Bowel Syndrome Correlates With Sensory but Not Motility Related Clinical Scores, and Is Dependent on the Functional Expression of NaV1.9. Gastroenterology, 2016, 150, S17.	1.3	1
368	Gastric secretion of amoxicillin and metronidazole, but not clarithromycin, is increased by pronase, a luminal mucolytic. Gastroenterology, 2001, 120, A119-A119.	1.3	1
369	MKC-733, a selective 5-HT3 receptor agonist, stimulates fasting human antral motility. Gastroenterology, 2001, 120, A460-A461.	1.3	1
370	MRI of gastric function. Special Publication - Royal Society of Chemistry, 0, , 85-97.	0.0	1
371	Peter Hubert Smith. BMJ: British Medical Journal, 2009, 338, b2633-b2633.	2.3	1
372	Brachyspira and IBS with diarrhoea: a Helicobacter pylori moment?. Gut, 2021, 70, 1-2.	12.1	1
373	Small intestine. Current Opinion in Gastroenterology, 1990, 6, 233-235.	2.3	0
374	Small intestine. Current Opinion in Gastroenterology, 1991, 7, 199-201.	2.3	0
375	Small intestine. Current Opinion in Gastroenterology, 1992, 8, 203-207.	2.3	0
376	Specialist training in the UK. Lancet, The, 1997, 350, 1850.	13.7	0
377	Persistence and resolution of symptoms and inflammation in Campylobacter enteritis. Gastroenterology, 1998, 114, A1099.	1.3	0
378	Gastric metronidazole transfer in a new model of Helicobacter pylori gastritis. Gastroenterology, 2000, 118, A1305.	1.3	0

#	Article	IF	CITATIONS
379	An improved model and HPLC assay for studying gastric amoxicillin transfer. Gastroenterology, 2000, 118, A501.	1.3	0
380	Gastric amoxicillin transfer in Helicobacter pylori +VE patients: Effect of bile reflux. Gastroenterology, 2000, 118, A1306.	1.3	0
381	Could the duration of anti-Helicobacter pylori treatment be shorter?. Digestive and Liver Disease, 2000, 32, 281-284.	0.9	0
382	The CCK1 receptor antagonist dexloxiglumide does not increase the risk of gallstone formation. Gastroenterology, 2000, 118, A1166.	1.3	0
383	Characterisation of strain dependent Campylobacter jejuni pathogenicity. Gastroenterology, 2000, 118, A99.	1.3	0
384	Echo-planar magnetic resonance imaging of gaviscon alginate rafts in humans. Gastroenterology, 2001, 120, A433-A434.	1.3	0
385	Treatment of functional GI disease: the complex pharmacology of serotonergic drugs. Reply from author. British Journal of Clinical Pharmacology, 2002, 54, 681-682.	2.4	0
386	Patients with untreated celiac disease have markedly elevated postprandial plasma serotonin responses. Gastroenterology, 2003, 124, A301-A302.	1.3	0
387	Can paroxetine improve well-being in patients with irritable bowel syndrome who do not respond to a high-fiber diet?. Nature Reviews Gastroenterology & Hepatology, 2004, 1, 14-15.	1.7	0
388	Double lumen duodenum in a patient with melaena. Gut, 2008, 57, 343-343.	12.1	0
389	Dysphagia and a skin rash. Gut, 2008, 57, 672-672.	12.1	0
390	An unusual bleeding duodenal ulcer. Gut, 2008, 57, 373-373.	12.1	0
391	A man with two pylori. Gut, 2008, 57, 305-305.	12.1	0
392	The year in Gut 2009. Gut, 2009, 58, 1569-1570.	12.1	0
393	OC-086â€Model for specialist-led "acute gastroenterology service― development and delivery. Gut, 2010, 59, A35.3-A36.	12.1	0
394	Increased Intra Epithelial Lymphocytes and Decreased Mucosal Mast Cells in a Mexican Population Compared to the United Kingdom: Effects of Childhood Living Conditions. Gastroenterology, 2011, 140, S-533.	1.3	0
395	Quantitative magnetic resonance imaging (MRI) in the evaluation of the degree of steatosis, iron accumulation and fibrosis in chronic liver diseases (MRKER STUDY). Gut, 2011, 60, A55-A56.	12.1	0
396	OC-091â€Ondansetron slows transit and improves stool consistency in patients with diarrhoea predominant irritable bowel syndrome. Gut, 2012, 61, A39.3-A40.	12.1	0

#	Article	IF	CITATIONS
397	OC-032â€A New Validated whole Gut Transit Time (WGTT) Measurement using Magnetic Resonance Imaging (Mri-Wgtt) Technique. Gut, 2013, 62, A14.1-A14.	12.1	0
398	PTU-127â€The Macrogol MRI Challenge Test: A Novel Non Invasive Colonic Function Test. Gut, 2013, 62, A98.2-A99.	12.1	0
399	OC-069â€Mesalazine For Treatment Of Diarrhoea-predominant Irritable Bowel Syndrome (ibs-d): A Multi-centre, Parallel Group, Randomised Placebo Controlled Trial: Abstract OC-069 Table 1. Gut, 2014, 63, A34-A34.	12.1	0
400	Editorial: abnormal permeability and altered mucosal serotonin metabolism in the irritable bowel syndrome - is there a link?. Alimentary Pharmacology and Therapeutics, 2014, 40, 1116-1118.	3.7	0
401	PWE-171â€Assessing The Utility Of Key Mri Parameters In Characterising The Mode Of Action Of A Proven Effective Laxative, Ispaghula. Gut, 2014, 63, A200-A200.	12.1	0
402	PTU-257ÂCorrelation of adipokines and intestinal inflammation with mesenteric adipose tissue volumes in symptomatic and asymptomatic diverticulosis: Abstract PTU-257 Table 1. Gut, 2015, 64, A174.2-A175.	12.1	0
403	PTU-333ÂClostridium difficile infection rate of recurrence is lower, and mortality is higher, in a large teaching hospital trust than in clinical trials: a prospective observational study. Gut, 2015, 64, A208.2-A209.	12.1	0
404	OC-067â€Different Mechanisms of Disease in Subtypes of Irritable Bowel Syndrome as Demonstrated by MRI: Abstract OC-067 Table 1. Gut, 2016, 65, A40.1-A40.	12.1	0
405	368 Associations Between Microbiota, Colonic Volume and Transit and the Low FODMAP Diet With and Without Added Oligofructose. Gastroenterology, 2016, 150, S82.	1.3	0
406	Su1577 MRI Shows Increased Water and Gas in the Bowel of Constipated Patients After Psyllium. Gastroenterology, 2016, 150, S531.	1.3	0
407	Response to Uno. American Journal of Gastroenterology, 2017, 112, 1167.	0.4	0
408	PWE-050â€Follow-on rifaximin for the prevention of recurrence in clostridium difficile associated diarrhoea: a randomised controlled trial. , 2017, , .		0
409	PWE-041â€Alteration in small bowel motility, gut peptides and patient's symptoms in active crohn's disease. , 2018, , .		0
410	Glycaemic, gastrointestinal, hormonal and appetite responses to pearl millet and oats porridge breakfast: a randomized, crossover trial. Proceedings of the Nutrition Society, 2018, 77, .	1.0	0
411	Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea—are we any closer? Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 826-827.	3.7	0
412	Enhancing our understanding of small bowel function using modern imaging techniques. Neurogastroenterology and Motility, 2020, 32, e13616.	3.0	0
413	O55 Lactulose increases small bowel but not colonic water content; questioning the osmotic laxative dogma. , 2021, , .		0
414	O59â€MRI methods to define colonic function in health and constipation. , 2021, , .		0

O59â \in ...MRI methods to define colonic function in health and constipation. , 2021, , . 414

#	Article	IF	CITATIONS
415	Effect of Helicobacter gastritis on gastric antibiotic transfer in man. Gastroenterology, 2001, 120, A587-A588.	1.3	0
416	MKC-733, A selective 5-HT3 receptor agonist, stimulates small bowel transit and relaxes the gastric fundus in man. Gastroenterology, 2001, 120, A71-A71.	1.3	0
417	Entero-endocrine cells are elevated in diarrhoea-predominant irritable bowel syndrome. Gastroenterology, 2001, 120, A751-A751.	1.3	0
418	Drug treatment of irritable bowel syndrome — different approaches for different subgroups?. , 2009, , 42-53.		0
419	Surgery for pancreatic cancer. BMJ: British Medical Journal, 1994, 308, 1715-1715.	2.3	0
420	Irritable bowel syndrome: Bacteria and inflammation—Clinical relevance now. Current Treatment Options in Cardiovascular Medicine, 2007, 10, 312-321.	0.9	0
421	Pain in diverticular diseases. , 0, , 111-119.		0
422	State-of-the Art Lecture: Irritable bowel syndrome: the new inflammatory bowel disease?. , 0, , 269-278.		0
423	Colonic diverticular disease: medical treatments for acute diverticulitis. Clinical Evidence, 2016, 2016, .	0.2	0
424	No cause for alarm in IBS. Practitioner, 2002, 246, 557.	0.3	0
495	Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and	0.4	0 -

⁴²⁵ symptoms. American Journal of Gastroenterology, 2002, 97, 2315-2320.